159 related articles for article (PubMed ID: 38175429)
1. The role of IgG4-positive plasma cell population in classic Hodgkin lymphoma.
Guler B; Tekden BC; Cetin G; Yildiz P; Turna S; Uysal O; Sinal I
J Hematop; 2023 Dec; 16(4):191-197. PubMed ID: 38175429
[TBL] [Abstract][Full Text] [Related]
2. High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.
Gholiha AR; Hollander P; Hedstrom G; Sundstrom C; Molin D; Smedby KE; Hjalgrim H; Glimelius I; Amini RM; Enblad G
Br J Haematol; 2019 Jan; 184(2):192-201. PubMed ID: 30506671
[TBL] [Abstract][Full Text] [Related]
3. Increased IgG4-positive plasma cells in nodular-sclerosing Hodgkin lymphoma: a diagnostic pitfall.
Nowak V; Agaimy A; Kristiansen G; Gütgemann I
Histopathology; 2020 Jan; 76(2):244-250. PubMed ID: 31373020
[TBL] [Abstract][Full Text] [Related]
4. A high number of IgG4-positive plasma cells rules out nodular lymphocyte predominant Hodgkin lymphoma.
Kiil K; Bein J; Schuhmacher B; Thurner L; Schneider M; Hansmann ML; Hartmann S
Virchows Arch; 2018 Dec; 473(6):759-764. PubMed ID: 30259184
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary nodular lymphoid hyperplasia (pulmonary pseudolymphoma): the significance of increased numbers of IgG4-positive plasma cells.
Guinee DG; Franks TJ; Gerbino AJ; Murakami SS; Acree SC; Koss MN
Am J Surg Pathol; 2013 May; 37(5):699-709. PubMed ID: 23588364
[TBL] [Abstract][Full Text] [Related]
6. Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.
Perry AM; Smith LB; Bagg A
Acta Med Acad; 2021 Apr; 50(1):110-125. PubMed ID: 34075767
[TBL] [Abstract][Full Text] [Related]
7. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.
Carbone A; Gloghini A; Caruso A; De Paoli P; Dolcetti R
Int J Cancer; 2017 Mar; 140(6):1233-1245. PubMed ID: 27750386
[TBL] [Abstract][Full Text] [Related]
8. Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging.
Lyapichev KA; You MJ; Vega F; Solis LM; Medeiros LJ
Virchows Arch; 2020 Sep; 477(3):437-444. PubMed ID: 32152665
[TBL] [Abstract][Full Text] [Related]
9. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.
Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C
J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
12. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
[TBL] [Abstract][Full Text] [Related]
13. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma.
van Bladel DAG; Stevens WBC; Kroeze LI; de Groen RAL; de Groot FA; van der Last-Kempkes JLM; Berendsen MR; Rijntjes J; Luijks JACW; Bonzheim I; van der Spek E; Plattel WJ; Pruijt JFM; de Jonge-Peeters SDPWM; Velders GA; Lensen C; van Bladel ER; Federmann B; Hoevenaars BM; Pastorczak A; van der Werff Ten Bosch J; Vermaat JSP; Nooijen PTGA; Hebeda KM; Fend F; Diepstra A; van Krieken JHJM; Groenen PJTA; van den Brand M; Scheijen B
Blood Adv; 2023 Oct; 7(19):5911-5924. PubMed ID: 37552109
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment.
Post GR; Yuan Y; Holthoff ER; Quick CM; Post SR
PLoS One; 2019; 14(11):e0224621. PubMed ID: 31714922
[TBL] [Abstract][Full Text] [Related]
15. Pathological count of IgG4-positive plasmacytes suggests extraophthalmic involvement and relapse in patients with IgG4-related ophthalmic disease: a retrospective study.
Yuan Y; Meng F; Ren H; Yue H; Xue K; Zhang R
Arthritis Res Ther; 2022 Apr; 24(1):80. PubMed ID: 35365184
[TBL] [Abstract][Full Text] [Related]
16. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.
Tudor CS; Distel LV; Eckhardt J; Hartmann A; Niedobitek G; Buettner M
Hum Pathol; 2013 Nov; 44(11):2475-86. PubMed ID: 24029709
[TBL] [Abstract][Full Text] [Related]
17. Tislelizumab for the treatment of classical Hodgkin's lymphoma.
Chen J; Zhang H; Zhu L; Zhao Y; Ding Y; Yuan Y
Drugs Today (Barc); 2020 Dec; 56(12):781-785. PubMed ID: 33332484
[TBL] [Abstract][Full Text] [Related]
18. [Pathological significance of plasma cell infiltration in diagnosing lymph node diseases].
Hu H; Jiang YJ; Xu L; Yin LJ; Liu XF; Yin SY; Xu JJ; He MX
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):702-709. PubMed ID: 37408401
[No Abstract] [Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
